David A Carlin

2.2k total citations · 1 hit paper
12 papers, 1.6k citations indexed

About

David A Carlin is a scholar working on Epidemiology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David A Carlin has authored 12 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Epidemiology, 4 papers in Surgery and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David A Carlin's work include Respiratory viral infections research (6 papers), Viral gastroenteritis research and epidemiology (2 papers) and Diabetes and associated disorders (2 papers). David A Carlin is often cited by papers focused on Respiratory viral infections research (6 papers), Viral gastroenteritis research and epidemiology (2 papers) and Diabetes and associated disorders (2 papers). David A Carlin collaborates with scholars based in United States, Sweden and South Korea. David A Carlin's co-authors include Franklin H. Top, Edward M. Connor, H. Cody Meissner, Allison K. Cabalka, Timothy F. Feltes, Franco M. Piazza, Henry M. Sondheimer, Syd Johnson, Scott Koenig and Johnny Ludvigsson and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Diabetes.

In The Last Decade

David A Carlin

12 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

2003 582 citations Timothy F. Feltes, Allison K. Cabalka et al. The Journal of Pediatrics profile →

Peers

David A Carlin

EPIDE

SURGE

PRM

GENET

EDM

P Quandallé France

Orhan Sezgın Türkiye

Jean-Paul Chigot France

J.C.M. Shastry India

Fiorella Balli Italy

E. Hafner Austria

D J Pudifin South Africa

George T. Hensley United States

Young‐Soo Shim South Korea

S. Granberg Sweden

P Quandallé France

David A Carlin

335 ×0.4

EPIDE

603 ×0.9

SURGE

189 ×0.3

PRM

416 ×0.9

GENET

26 ×0.1

EDM

Citations per year, relative to David A Carlin David A Carlin (= 1×) peers P Quandallé

Countries citing papers authored by David A Carlin

Since Specialization

Citations

This map shows the geographic impact of David A Carlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A Carlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A Carlin more than expected).

Fields of papers citing papers by David A Carlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A Carlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A Carlin. The network helps show where David A Carlin may publish in the future.

Co-authorship network of co-authors of David A Carlin

This figure shows the co-authorship network connecting the top 25 collaborators of David A Carlin. A scholar is included among the top collaborators of David A Carlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A Carlin. David A Carlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Burris, Howard A., Giuseppe Giaccone, Seock‐Ah Im, et al.. (2015). Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). 523–523. 3 indexed citations

Hagopian, William, Robert J. Ferry, Nicole Sherry, et al.. (2013). Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes. Diabetes. 62(11). 3901–3908. 173 indexed citations

Burris, Howard A., Giuseppe Giaccone, Seock‐Ah Im, et al.. (2013). Phase I study of margetuximab (MGAH22), an FC-modified chimeric monoclonal antibody (MAb), in patients (pts) with advanced solid tumors expressing the HER2 oncoprotein.. Journal of Clinical Oncology. 31(15_suppl). 3004–3004. 6 indexed citations

Sherry, Nicole, William Hagopian, Johnny Ludvigsson, et al.. (2011). Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. The Lancet. 378(9790). 487–497. 363 indexed citations

Null, Donald M., Bernard Pollara, Penelope H. Dennehy, et al.. (2005). SAFETY AND IMMUNOGENICITY OF PALIVIZUMAB (SYNAGIS) ADMINISTERED FOR TWO SEASONS. The Pediatric Infectious Disease Journal. 24(11). 1021–1023. 26 indexed citations

Feltes, Timothy F., Allison K. Cabalka, H. Cody Meissner, et al.. (2003). Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. The Journal of Pediatrics. 143(4). 532–540. 582 indexed citations breakdown →

Blanke, Charles D., Jeffrey Shultz, James D. Cox, et al.. (2002). A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. Annals of Oncology. 13(1). 87–91. 24 indexed citations

Johnson, Syd, David S. Pfarr, Michael L. Doyle, et al.. (1999). A Direct Comparison of the Activities of Two Humanized Respiratory Syncytial Virus Monoclonal Antibodies: MEDI‐493 and RSHZl9. The Journal of Infectious Diseases. 180(1). 35–40. 77 indexed citations

Subramanian, K. N. Siva, Ronald L. Ariagno, Pablo J. Sánchez, et al.. (1998). Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The Pediatric Infectious Disease Journal. 17(2). 110–115. 166 indexed citations

10.

Malley, Richard, John P. DeVincenzo, Octavio Ramilo, et al.. (1998). Reduction of Respiratory Syncytial Virus (RSV) in Tracheal Aspirates in Intubated Infants by Use of Humanized Monoclonal Antibody to RSV F Protein. The Journal of Infectious Diseases. 178(6). 1555–1561. 178 indexed citations

11.

DeVincenzo, John P., Richard Malley, Octavio Ramilo, et al.. (1998). Viral Concentration in Upper and Lower Respiratory Secretions from Respiratory Syncytial Virus (RSV) Infected Children Treated with RSV Monoclonal Antibody (MEDI-493) † 830. Pediatric Research. 43. 144–144. 3 indexed citations

12.

LEIKER, D. L. & David A Carlin. (1966). Low Dosage of DDS. Leprosy Review. 37(1). 27–9. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact